Corindus Vascular Robotics Inc (NYSEMKT:CVRS)’s share price traded down 0% during mid-day trading on Monday . The company traded as low as $0.77 and last traded at $0.79. 863,759 shares changed hands during trading, an increase of 2% from the average session volume of 849,480 shares. The stock had previously closed at $0.79.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Corindus Vascular Robotics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Tuesday, August 29th. BidaskClub raised shares of Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine downgraded shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, Cowen and Company set a $3.00 price objective on shares of Corindus Vascular Robotics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $2.33.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings results on Tuesday, November 7th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative return on equity of 94.27% and a negative net margin of 372.63%. The firm had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $3.60 million.

A number of institutional investors and hedge funds have recently modified their holdings of CVRS. Vanguard Group Inc. boosted its stake in shares of Corindus Vascular Robotics by 57.6% during the second quarter. Vanguard Group Inc. now owns 3,279,185 shares of the medical equipment provider’s stock valued at $6,100,000 after purchasing an additional 1,198,384 shares during the period. Essex Investment Management Co. LLC purchased a new stake in Corindus Vascular Robotics in the third quarter worth $1,213,000. Northern Trust Corp lifted its stake in Corindus Vascular Robotics by 42.4% in the second quarter. Northern Trust Corp now owns 959,920 shares of the medical equipment provider’s stock worth $1,786,000 after acquiring an additional 285,811 shares during the period. Geode Capital Management LLC lifted its stake in Corindus Vascular Robotics by 73.3% in the first quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock worth $882,000 after acquiring an additional 284,855 shares during the period. Finally, State Street Corp lifted its stake in Corindus Vascular Robotics by 44.3% in the second quarter. State Street Corp now owns 926,439 shares of the medical equipment provider’s stock worth $1,724,000 after acquiring an additional 284,507 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/corindus-vascular-robotics-inc-cvrs-stock-price-down-0/1701166.html.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.